DNA-Engineered Degradable Invisibility Cloaking for Tumor-Targeting Nanoparticles

Nanoparticle (NP) delivery systems have been actively exploited for cancer therapy and vaccine development. Nevertheless, the major obstacle to targeted delivery lies in the substantial liver sequestration of NPs. Here we report a DNA-engineered approach to circumvent liver phagocytosis for enhanced...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American Chemical Society 2024-09, Vol.146 (36), p.25253-25262
Main Authors: Zhao, Yan, Hou, Junjun, Guo, Linjie, Zhu, Shitai, Hou, Xiaoling, Cao, Shuting, Zhou, Mo, Shi, Jiye, Li, Jiang, Liu, Kai, Zhang, Hongjie, Wang, Lihua, Fan, Chunhai, Zhu, Ying
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nanoparticle (NP) delivery systems have been actively exploited for cancer therapy and vaccine development. Nevertheless, the major obstacle to targeted delivery lies in the substantial liver sequestration of NPs. Here we report a DNA-engineered approach to circumvent liver phagocytosis for enhanced tumor-targeted delivery of nanoagents in vivo. We find that a monolayer of DNA molecules on the NP can preferentially adsorb a dysopsonin protein in the serum to induce functionally invisibility to livers; whereas the tumor-specific uptake is triggered by the subsequent degradation of the DNA shell in vivo. The degradation rate of DNA shells is readily tunable by the length of coated DNA molecules. This DNA-engineered invisibility cloaking (DEIC) is potentially generic as manifested in both Ag2S quantum dot- and nanoliposome-based tumor-targeted delivery in mice. Near-infrared-II imaging reveals a high tumor-to-liver ratio of up to ∼5.1, approximately 18-fold higher than those with conventional nanomaterials. This approach may provide a universal strategy for high-efficiency targeted delivery of theranostic agents in vivo.
ISSN:0002-7863
1520-5126
1520-5126
DOI:10.1021/jacs.4c09479